ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000031

Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients

Identifieur interne : 000031 ( PascalFrancis/Corpus ); précédent : 000030; suivant : 000032

Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients

Auteurs : Santiago Perez-Lloret ; María Ver Nica Rey ; James Crispo ; Daniel Krewski ; Marise Lapeyre-Mestre ; Jean-Louis Montastruc ; Olivier Rascol

Source :

Expert opinion on drug safety [ 1474-0338 ] ; 2014.

RBID : Pascal:14-0095204

Descripteurs français

Pascal (Inist)
- Facteur risque, Insuffisance cardiaque, Traitement, Stimulant dopaminergique, Maladie de Parkinson, Homme, Toxicité, Médicament, Pathologie de l'appareil circulatoire, Pharmacovigilance, Pramipexole, Article synthèse, Revue bibliographique, Antiparkinsonien, Neuroprotecteur.

English descriptors

KwdEn :
- Antiparkinson agent, Bibliographic review, Cardiovascular disease, Dopamine agonist, Drug, Heart failure, Human, Neuroprotective agent, Parkinson disease, Pharmacovigilance, Pramipexole, Review, Risk factor, Toxicity, Treatment.

Abstract

Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1474-0338`
A03		`1`		`@0 Expert opin. drug saf.`
A05				`@2 13`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients`
A11	`01`	`1`		`@1 PEREZ-LLORET (Santiago)`
A11	`02`	`1`		`@1 REY (María Verónica)`
A11	`03`	`1`		`@1 CRISPO (James)`
A11	`04`	`1`		`@1 KREWSKI (Daniel)`
A11	`05`	`1`		`@1 LAPEYRE-MESTRE (Marise)`
A11	`06`	`1`		`@1 MONTASTRUC (Jean-Louis)`
A11	`07`	`1`		`@1 RASCOL (Olivier)`
A14	`01`			`@1 Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences @2 Toulouse @3 FRA @Z 1 aut. @Z 2 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A14	`02`			`@1 University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street @2 Ottawa, Ontario, K1N 6N5 @3 CAN @Z 3 aut. @Z 4 aut.`
A14	`03`			`@1 Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde @2 31000, Toulouse @3 FRA @Z 7 aut.`
A20				`@1 351-360`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 28166 @5 354000501182730090`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 61 ref.`
A47	`01`	`1`		`@0 14-0095204`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Expert opinion on drug safety`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.
C02	`01`	`X`		`@0 002B02U`
C02	`02`	`X`		`@0 002B12A01`
C02	`03`	`X`		`@0 002B17G`
C02	`04`	`X`		`@0 002B17A01`
C03	`01`	`X`	`FRE`	`@0 Facteur risque @5 01`
C03	`01`	`X`	`ENG`	`@0 Risk factor @5 01`
C03	`01`	`X`	`SPA`	`@0 Factor riesgo @5 01`
C03	`02`	`X`	`FRE`	`@0 Insuffisance cardiaque @5 02`
C03	`02`	`X`	`ENG`	`@0 Heart failure @5 02`
C03	`02`	`X`	`SPA`	`@0 Insuficiencia cardíaca @5 02`
C03	`03`	`X`	`FRE`	`@0 Traitement @5 03`
C03	`03`	`X`	`ENG`	`@0 Treatment @5 03`
C03	`03`	`X`	`SPA`	`@0 Tratamiento @5 03`
C03	`04`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 04`
C03	`04`	`X`	`ENG`	`@0 Dopamine agonist @5 04`
C03	`04`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 04`
C03	`05`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 05`
C03	`05`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 05`
C03	`05`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 05`
C03	`06`	`X`	`FRE`	`@0 Homme @5 06`
C03	`06`	`X`	`ENG`	`@0 Human @5 06`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 06`
C03	`07`	`X`	`FRE`	`@0 Toxicité @5 07`
C03	`07`	`X`	`ENG`	`@0 Toxicity @5 07`
C03	`07`	`X`	`SPA`	`@0 Toxicidad @5 07`
C03	`08`	`X`	`FRE`	`@0 Médicament @5 08`
C03	`08`	`X`	`ENG`	`@0 Drug @5 08`
C03	`08`	`X`	`SPA`	`@0 Medicamento @5 08`
C03	`09`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 09`
C03	`09`	`X`	`ENG`	`@0 Cardiovascular disease @5 09`
C03	`09`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 09`
C03	`10`	`X`	`FRE`	`@0 Pharmacovigilance @5 10`
C03	`10`	`X`	`ENG`	`@0 Pharmacovigilance @5 10`
C03	`10`	`X`	`SPA`	`@0 Farmacovigilancia @5 10`
C03	`11`	`X`	`FRE`	`@0 Pramipexole @2 NK @2 FR @5 11`
C03	`11`	`X`	`ENG`	`@0 Pramipexole @2 NK @2 FR @5 11`
C03	`11`	`X`	`SPA`	`@0 Pramipexol @2 NK @2 FR @5 11`
C03	`12`	`X`	`FRE`	`@0 Article synthèse @5 12`
C03	`12`	`X`	`ENG`	`@0 Review @5 12`
C03	`12`	`X`	`SPA`	`@0 Artículo síntesis @5 12`
C03	`13`	`X`	`FRE`	`@0 Revue bibliographique @5 13`
C03	`13`	`X`	`ENG`	`@0 Bibliographic review @5 13`
C03	`13`	`X`	`SPA`	`@0 Revista bibliográfica @5 13`
C03	`14`	`X`	`FRE`	`@0 Antiparkinsonien @5 23`
C03	`14`	`X`	`ENG`	`@0 Antiparkinson agent @5 23`
C03	`14`	`X`	`SPA`	`@0 Antiparkinsoniano @5 23`
C03	`15`	`X`	`FRE`	`@0 Neuroprotecteur @5 24`
C03	`15`	`X`	`ENG`	`@0 Neuroprotective agent @5 24`
C03	`15`	`X`	`SPA`	`@0 Neuroprotector @5 24`
C07	`01`	`X`	`FRE`	`@0 Cardiopathie @5 37`
C07	`01`	`X`	`ENG`	`@0 Heart disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Cardiopatía @5 37`
C07	`02`	`X`	`FRE`	`@0 Maladie dégénérative @5 38`
C07	`02`	`X`	`ENG`	`@0 Degenerative disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 39`
C07	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 39`
C07	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 40`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 40`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 41`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 41`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 41`
C07	`06`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 42`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 42`
C07	`07`	`X`	`FRE`	`@0 Agoniste @5 43`
C07	`07`	`X`	`ENG`	`@0 Agonist @5 43`
C07	`07`	`X`	`SPA`	`@0 Agonista @5 43`
C07	`08`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 44`
C07	`08`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 44`
C07	`08`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 44`
N21				`@1 132`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0095204 INIST
ET :	Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
AU :	PEREZ-LLORET (Santiago); REY (María Verónica); CRISPO (James); KREWSKI (Daniel); LAPEYRE-MESTRE (Marise); MONTASTRUC (Jean-Louis); RASCOL (Olivier)
AF :	Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences/Toulouse/France (1 aut., 2 aut., 5 aut., 6 aut., 7 aut.); University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street/Ottawa, Ontario, K1N 6N5/Canada (3 aut., 4 aut.); Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde/31000, Toulouse/France (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Expert opinion on drug safety; ISSN 1474-0338; Royaume-Uni; Da. 2014; Vol. 13; No. 3; Pp. 351-360; Bibl. 61 ref.
LA :	Anglais
EA :	Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.
CC :	002B02U; 002B12A01; 002B17G; 002B17A01
FD :	Facteur risque; Insuffisance cardiaque; Traitement; Stimulant dopaminergique; Maladie de Parkinson; Homme; Toxicité; Médicament; Pathologie de l'appareil circulatoire; Pharmacovigilance; Pramipexole; Article synthèse; Revue bibliographique; Antiparkinsonien; Neuroprotecteur
FG :	Cardiopathie; Maladie dégénérative; Pathologie du système nerveux; Pathologie de l'encéphale; Syndrome extrapyramidal; Pathologie du système nerveux central; Agoniste; Récepteur dopaminergique D2
ED :	Risk factor; Heart failure; Treatment; Dopamine agonist; Parkinson disease; Human; Toxicity; Drug; Cardiovascular disease; Pharmacovigilance; Pramipexole; Review; Bibliographic review; Antiparkinson agent; Neuroprotective agent
EG :	Heart disease; Degenerative disease; Nervous system diseases; Cerebral disorder; Extrapyramidal syndrome; Central nervous system disease; Agonist; D2 Dopamine receptor
SD :	Factor riesgo; Insuficiencia cardíaca; Tratamiento; Estimulante dopaminérgico; Parkinson enfermedad; Hombre; Toxicidad; Medicamento; Aparato circulatorio patología; Farmacovigilancia; Pramipexol; Artículo síntesis; Revista bibliográfica; Antiparkinsoniano; Neuroprotector
LO :	INIST-28166.354000501182730090
ID :	14-0095204

Links to Exploration step

Pascal:14-0095204

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients</title>
<author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
<affiliation><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name>
<affiliation><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Crispo, James" sort="Crispo, James" uniqKey="Crispo J" first="James" last="Crispo">James Crispo</name>
<affiliation><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1>
<s2>Ottawa, Ontario, K1N 6N5</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name>
<affiliation><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1>
<s2>Ottawa, Ontario, K1N 6N5</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lapeyre Mestre, Marise" sort="Lapeyre Mestre, Marise" uniqKey="Lapeyre Mestre M" first="Marise" last="Lapeyre-Mestre">Marise Lapeyre-Mestre</name>
<affiliation><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde</s1>
<s2>31000, Toulouse</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0095204</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0095204 INIST</idno>
<idno type="RBID">Pascal:14-0095204</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000031</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients</title>
<author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
<affiliation><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name>
<affiliation><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Crispo, James" sort="Crispo, James" uniqKey="Crispo J" first="James" last="Crispo">James Crispo</name>
<affiliation><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1>
<s2>Ottawa, Ontario, K1N 6N5</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name>
<affiliation><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1>
<s2>Ottawa, Ontario, K1N 6N5</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lapeyre Mestre, Marise" sort="Lapeyre Mestre, Marise" uniqKey="Lapeyre Mestre M" first="Marise" last="Lapeyre-Mestre">Marise Lapeyre-Mestre</name>
<affiliation><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde</s1>
<s2>31000, Toulouse</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Expert opinion on drug safety</title>
<title level="j" type="abbreviated">Expert opin. drug saf.</title>
<idno type="ISSN">1474-0338</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Expert opinion on drug safety</title>
<title level="j" type="abbreviated">Expert opin. drug saf.</title>
<idno type="ISSN">1474-0338</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Bibliographic review</term>
<term>Cardiovascular disease</term>
<term>Dopamine agonist</term>
<term>Drug</term>
<term>Heart failure</term>
<term>Human</term>
<term>Neuroprotective agent</term>
<term>Parkinson disease</term>
<term>Pharmacovigilance</term>
<term>Pramipexole</term>
<term>Review</term>
<term>Risk factor</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Facteur risque</term>
<term>Insuffisance cardiaque</term>
<term>Traitement</term>
<term>Stimulant dopaminergique</term>
<term>Maladie de Parkinson</term>
<term>Homme</term>
<term>Toxicité</term>
<term>Médicament</term>
<term>Pathologie de l'appareil circulatoire</term>
<term>Pharmacovigilance</term>
<term>Pramipexole</term>
<term>Article synthèse</term>
<term>Revue bibliographique</term>
<term>Antiparkinsonien</term>
<term>Neuroprotecteur</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1474-0338</s0>
</fA01>
<fA03 i2="1"><s0>Expert opin. drug saf.</s0>
</fA03>
<fA05><s2>13</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PEREZ-LLORET (Santiago)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>REY (María Verónica)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CRISPO (James)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KREWSKI (Daniel)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LAPEYRE-MESTRE (Marise)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MONTASTRUC (Jean-Louis)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1>
<s2>Ottawa, Ontario, K1N 6N5</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde</s1>
<s2>31000, Toulouse</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>351-360</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>28166</s2>
<s5>354000501182730090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>61 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0095204</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Expert opinion on drug safety</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02U</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B12A01</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="04" i2="X"><s0>002B17A01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Insuffisance cardiaque</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Heart failure</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Insuficiencia cardíaca</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Médicament</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Drug</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Pharmacovigilance</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Pharmacovigilance</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Farmacovigilancia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Pramipexole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Pramipexole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Pramipexol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Review</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Revue bibliographique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Bibliographic review</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Revista bibliográfica</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>23</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Neuroprotecteur</s0>
<s5>24</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Neuroprotective agent</s0>
<s5>24</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Neuroprotector</s0>
<s5>24</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Cardiopathie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Heart disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Cardiopatía</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Agonist</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Agonista</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>44</s5>
</fC07>
<fN21><s1>132</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0095204 INIST</NO>
<ET>Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients</ET>
<AU>PEREZ-LLORET (Santiago); REY (María Verónica); CRISPO (James); KREWSKI (Daniel); LAPEYRE-MESTRE (Marise); MONTASTRUC (Jean-Louis); RASCOL (Olivier)</AU>
<AF>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences/Toulouse/France (1 aut., 2 aut., 5 aut., 6 aut., 7 aut.); University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street/Ottawa, Ontario, K1N 6N5/Canada (3 aut., 4 aut.); Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde/31000, Toulouse/France (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Expert opinion on drug safety; ISSN 1474-0338; Royaume-Uni; Da. 2014; Vol. 13; No. 3; Pp. 351-360; Bibl. 61 ref.</SO>
<LA>Anglais</LA>
<EA>Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.</EA>
<CC>002B02U; 002B12A01; 002B17G; 002B17A01</CC>
<FD>Facteur risque; Insuffisance cardiaque; Traitement; Stimulant dopaminergique; Maladie de Parkinson; Homme; Toxicité; Médicament; Pathologie de l'appareil circulatoire; Pharmacovigilance; Pramipexole; Article synthèse; Revue bibliographique; Antiparkinsonien; Neuroprotecteur</FD>
<FG>Cardiopathie; Maladie dégénérative; Pathologie du  système nerveux; Pathologie de l'encéphale; Syndrome extrapyramidal; Pathologie du   système nerveux central; Agoniste; Récepteur dopaminergique D2</FG>
<ED>Risk factor; Heart failure; Treatment; Dopamine agonist; Parkinson disease; Human; Toxicity; Drug; Cardiovascular disease; Pharmacovigilance; Pramipexole; Review; Bibliographic review; Antiparkinson agent; Neuroprotective agent</ED>
<EG>Heart disease; Degenerative disease; Nervous system diseases; Cerebral disorder; Extrapyramidal syndrome; Central nervous system disease; Agonist; D2 Dopamine receptor</EG>
<SD>Factor riesgo; Insuficiencia cardíaca; Tratamiento; Estimulante dopaminérgico; Parkinson enfermedad; Hombre; Toxicidad; Medicamento; Aparato circulatorio patología; Farmacovigilancia; Pramipexol; Artículo síntesis; Revista bibliográfica; Antiparkinsoniano; Neuroprotector</SD>
<LO>INIST-28166.354000501182730090</LO>
<ID>14-0095204</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000031 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000031 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0095204
   |texte=   Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients

Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri